LiquidiaLQDA
LQDA logo
Fair Value
US$72.38
Share price26 Jun
US$79.9410.5% overvalued intrinsic discount
Loading
1Y449.79%
7D2.58%

Manufacturing Expansion And Pulmonary Hypertension Pipeline Will Reshape Long Term Earnings Profile

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
06 Jan 26
Updated
26 Jun 26
Views
184
Not Invested

Fair Value vs Share Price

US$72.38
vs US$79.9410.5% overvalued intrinsic discount
PastFuture-152m1b20162018202020222024202620282029Revenue US$1.4bEarnings US$665.8m
68.6%
Revenue growth
48.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Liquidia

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

High growth potential with adequate balance sheet.

Market capUS$7.1b
PB65.5x
Estimated Growth25.0%
Dividend YieldN/A
Full analysis

CEO & management

Roger Jeffs
CEO
3.0yrs
CEO Tenure

A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.